Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

APEIRON Biologics AG, corporate

APEIRON Biologics AG,

12.03.2021 - 08:04:10

APEIRON's APN01 shows clinical benefits for severely ill COVID-19 patients in phase 2 trial

described the first named patient use of APN01, reporting encouraging data for APN01 for the treatment of COVID-19. The specific targeting of SARS-CoV-2 by APN01 was recently confirmed by preclinical results in human organoids (engineered human organs) and Vero E6 cells published in the peer reviewed journal CELL.

About APEIRON Biologics AG APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies.

APN01 (rhsACE2, alunacedase alfa), a soluble recombinant version of the SARS-CoV-2 cell entry receptor ACE2, has three distinct potential clinical benefits for COVID-19 and has completed a double blind, placebo-controlled Phase 2 trial in Europe and Russia.

APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba(R)) in 2017 for the treatment of pediatric neuroblastoma patients and out-licensed global, exclusive rights for this product to EUSA Pharma Ltd.

APN401's proprietary process brings in a paradigm change in cancer treatment to fight hematological and solid tumors. The clinical program is a first-in-class ambulatory autologous cellular therapy to strengthen immune reactivity via an intracellular master checkpoint inhibitor, Cbl-b.

APEIRON Biologics' projects and technologies are based on a strong patent portfolio and partnerships with leading pharmaceutical companies and academic institutions.

Further information, visit www.apeiron-biologics.com and connect with us on Twitter and LinkedIn.

For further information please contact:

APEIRON Biologics AG Peter Llewellyn-Davies CEO Email: investors@apeiron-biologics.comwww.apeiron-biologics.com

Media and Investor Relations MC Services AG Julia Hofmann, Andreas Jungfer T +49 89 210 228 0 Email: apeiron@mc-services.eu

FORWARD LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of APEIRON Biologics as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

12.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de


@ dgap.de